Sim Sung Jun, Cheong Jae Youn, Cho Sung Won, Kim Jong Su, Lim Tae Young, Shin Do Hyun, Lim Sun Gyo, Kim Young Bae, Lee Kee Myung, Yoo Byung Moo, Lee Kwang Jae, Hahm Ki Baik, Kim Jin Hong
Department of Gastroenterology, Ajou University College of Medicine, Suwon, Korea.
Korean J Gastroenterol. 2005 May;45(5):340-7.
BACKGROUND/AIMS: An ideal noninvasive diagnostic test for hepatic fibrosis should be simple, inexpensive, and accurate. We aimed to find the simple marker for predicting hepatic fibrosis and to compare the accuracy of AST, platelet, AST/ALT ratio and AST to platelet ratio index (APRI) in chronic hepatitis B patients without clinical evidence of cirrhosis.
A total of one hundred and twenty-six chronic hepatitis B patients who underwent liver biopsy at the Ajou University Hospital from August 1998 to December 2003 were enrolled. Hepatic fibrosis was assessed using the Ludwig classification. Significant fibrosis was defined as fibrosis score of 3 or more. The AST/ALT ratio and APRI were calculated and correlations with hepatic fibrosis were analyzed.
APRI showed a significant correlation (r=0.501, p=0.000) with hepatic fibrosis, and was superior to AST, AST/ALT ratio and platelet in predicting fibrosis. Patients with significant fibrosis (fibrosis stage 3, 4) can be identified to have APRI = 1 with sensitivity 71.2% and specificity 70.3%. The sensitivity and specificity of an APRI = 1.5 for cirrhosis (stage 4) were 83.3% and 75.0%.
Simple index using AST and platelet value can predict the presence of significant fibrosis and cirrhosis in chronic hepatitis B patients without clinical evidence of cirrhosis.
背景/目的:理想的肝纤维化无创诊断检测方法应具备简单、廉价且准确的特点。我们旨在寻找预测肝纤维化的简单标志物,并比较AST、血小板、AST/ALT比值及AST与血小板比值指数(APRI)在无肝硬化临床证据的慢性乙型肝炎患者中的准确性。
纳入1998年8月至2003年12月在韩国庆熙大学医院接受肝活检的126例慢性乙型肝炎患者。采用Ludwig分类法评估肝纤维化。显著纤维化定义为纤维化评分≥3分。计算AST/ALT比值及APRI,并分析其与肝纤维化的相关性。
APRI与肝纤维化显著相关(r = 0.501,p = 0.000),在预测纤维化方面优于AST、AST/ALT比值及血小板。显著纤维化(纤维化分期3、4期)患者APRI = 1时,敏感性为71.2%,特异性为70.3%。APRI = 1.5诊断肝硬化(4期)的敏感性和特异性分别为83.3%和75.0%。
利用AST和血小板值的简单指数可预测无肝硬化临床证据的慢性乙型肝炎患者是否存在显著纤维化及肝硬化。